Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgical Innovations GroupLSE:SUN Return-on-Tangible-Equity is -68.96% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Surgical Innovations Group ranks worse than 76.94% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Surgical Innovations Group's annualized net income for the quarter that ended in Dec. 2025 was £-1.83 Mil. Surgical Innovations Group's average shareholder tangible equity for the quarter that ended in Dec. 2025 was £2.66 Mil. Therefore, Surgical Innovations Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -68.96%.
The historical rank and industry rank for Surgical Innovations Group's Return-on-Tangible-Equity or its related term are showing as below:
LSE:SUN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -69 Med: -10.85 Max: 21.09
Current: -31.85
During the past 13 years, Surgical Innovations Group's highest Return-on-Tangible-Equity was 21.09%. The lowest was -69.00%. And the median was -10.85%.
LSE:SUN's Return-on-Tangible-Equity is ranked worse than 76.94% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs LSE:SUN: -31.85
Surgical Innovations Group (LSE:SUN) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Surgical Innovations Group Return-on-Tangible-Equity Related Terms
Surgical Innovations Group Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Innovations Group Return-on-Tangible-Equity Chart
LSE:SUN vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Surgical Innovations Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Innovations Group Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Surgical Innovations Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Surgical Innovations Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -68.96% mean?
Surgical Innovations Group (LSE:SUN) has a Return-on-Tangible-Equity of -68.96% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Surgical Innovations Group and its competitors. According to the industry distribution chart, Surgical Innovations Group ranks #584 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 76.9%.
Is Surgical Innovations Group's Return-on-Tangible-Equity too high?
Surgical Innovations Group's current Return-on-Tangible-Equity is -68.96%. Based on the distribution chart, Surgical Innovations Group ranks #584 out of 759 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Surgical Innovations Group's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Surgical Innovations Group ranks #584 out of 759 companies for Return-on-Tangible-Equity. This places Surgical Innovations Group in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Surgical Innovations Group and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Innovations Group's current Return-on-Tangible-Equity is -68.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Innovations Group stock overvalued right now?
Based on GuruFocus' analysis, Surgical Innovations Group (LSE:SUN) is currently considered Possible Value Trap. The stock's GF Value™ is £0.01, compared to a current price of £0.01 — trading 50% below its estimated fair value. The current Return-on-Tangible-Equity is -68.96%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Surgical Innovations Group (LSE:SUN), the current Return-on-Tangible-Equity is -68.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Surgical Innovations Group PLC is involved in the design, development, manufacture, and sale of devices for use in minimally invasive surgery (SI Brand), along with its label products through original equipment manufacturer (OEM) relationships, including precision engineering markets (PE). The Company's operating segments are SI Brand, OEM, and Distribution. The majority of its revenue is generated from the SI Brand segment, which is involved in the research, development, manufacture, and distribution of SI-branded minimally invasive devices. Geographically, the group derives a majority of its revenue from the United Kingdom, followed by Europe, the United States, the Asia-Pacific region, and the Rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SUN has been successfully added to your 
